Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus ankara expressing HIV-1 antigens

Journal of Virology

Volumn 88, Issue 6, 2014, Pages 3392-3410

  García Arriaza, Juan ^a   Gómez, Carmen E ^a   Sorzano, Carlos Óscar S ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON REGULATORY FACTOR 3; NEF PROTEIN; POL PROTEIN; POXVIRUS VECTOR; PROTEIN N2; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; EMBRYO; FEMALE; GENE DELETION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; MEMORY IMMUNE RESPONSE; MODIFIED VACCINIA VIRUS ANKARA; MONOCYTE; MOUSE; N2L GENE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; VACCINIA; VACCINIA VIRUS; VIROGENESIS; VIRUS GENE; VIRUS GENOME; VIRUS STRAIN;

ANIMALS; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC VECTORS; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON REGULATORY FACTOR-3; MICE; MICE, INBRED BALB C; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84894542920     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02723-13     Document Type: Article

References (93)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
2. Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L. 2007. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44:203-212. http://dx.doi.org/10.1097/01.qai.0000248356.48501.ff.
3. Gómez CE, Perdiguero B, García-Arriaza J, Esteban M. 2012. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum. Vaccin. Immunother. 8:1192-1207. http://dx.doi.org/10.4161/hv.20778.
4. O'Connell RJ, Kim JH, Corey L, Michael NL. 2012. Human immunodeficiency virus vaccine trials. Cold Spring Harb. Perspect. Med. 2:a007351. http://dx.doi.org/10.1101/cshperspect.a007351.
5. Pantaleo G, Esteban M, Jacobs B, Tartaglia J. 2010. Poxvirus vectorbased HIV vaccines. Curr. Opin. HIV AIDS 5:391-396. http://dx.doi.org/10.1097/COH.0b013e32833d1e87.
6. Cottingham MG, Carroll MW. 2013. Recombinant MVA vaccines: dispelling the myths. Vaccine 31:4247-4251. http://dx.doi.org/10.1016/j.vaccine.2013.03.021.
7. Gómez CE, Perdiguero B, García-Arriaza J, Esteban M. 2013. Clinical applications of attenuated MVA poxvirus strain. Expert Rev. Vaccines 12:1395-1416. http://dx.doi.org/10.1586/14760584.2013.845531.
8. + T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1DNAvaccine and boosted with recombinant modified vaccinia virus Ankara expressing HIV-1 genes. Clin. Vaccine Immunol. 17:1124-1131. http://dx.doi.org/10.1128/CVI.00008-10.
9. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramírez K, Joachim A, Polonis VR, Brave A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E. 2011. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 29:8417-8428. http://dx.doi.org/10.1016/j.vaccine.2011.08.001.
10. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, Fast PE, Conlon C, Rowland-Jones S, McMichael AJ, Hanke T. 2006. Phase I clinical trial safety of DNA-and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a primeboost regime to healthy HIV-1-uninfected volunteers. Vaccine 24:417-425. http://dx.doi.org/10.1016/j.vaccine.2005.08.041.
11. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA. 2010. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5:e13983. http://dx.doi.org/10.1371/journal.pone.0013983.
12. García F, Bernaldo de Quiros JC, Gómez CE, Perdiguero B, Nájera JL, Jimenez V, García-Arriaza J, Guardo AC, Perez I, Diaz-Brito V, Conde MS, González N, Alvarez A, Alcami J, Jimenez JL, Pich J, Arnaiz JA, Maleno MJ, Leon A, Munoz-Fernandez MA, Liljestrom P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M. 2011. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol, and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 29:8309-8316. http://dx.doi.org/10.1016/j.vaccine.2011.08.098.
13. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL. 2011. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis. 203:610-619. http://dx.doi.org/10.1093/infdis/jiq105.
14. Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jimenez V, González-Sanz R, Jimenez JL, Munoz-Fernandez MA, Lopez Bernaldo de Quiros JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M. 2011. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J. Virol. 85:11468-11478. http://dx.doi.org/10.1128/JVI.05165-11.
15. + T-cell epitopes. J. Virol. 80:4717-4728. http://dx.doi.org/10.1128/JVI.80.10.4717-4728.2006.
16. Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B. 2009. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 27:4468-4474. http://dx.doi.org/10.1016/j.vaccine.2009.05.018.
17. Guimarães-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J, Barin B, McMichael A, Weber J, Legg K, Babiker A, Hayes P, Gotch F, Smith C, Dally L, Dorrell L, Cebere I, Kay R, Winstone N, Moore S, Goonetilleke N, Fast P. 2008. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 26: 6671-6677. http://dx.doi.org/10.1016/j.vaccine.2008.09.016.
18. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, Nanvubya A, Bashir F, Bhatt K, Ogutu H, Wakasiaka S, Matu L, Waruingi W, Odada J, Oyaro M, Indangasi J, Ndinya-Achola J, Konde C, Mugisha E, Fast P, Schmidt C, Gilmour J, Tarragona T, Smith C, Barin B, Dally L, Johnson B, Muluubya A, Nielsen L, Hayes P, Boaz M, Hughes P, Hanke T, McMichael A, Bwayo J, Kaleebu P. 2008. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26:2788-2795. http://dx.doi.org/10.1016/j.vaccine.2008.02.071.
19. Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L. 2011. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29:1948-1958. http://dx.doi.org/10.1016/j.vaccine.2010.12.104.
20. Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, Verma A, Kurle S, Shrotri A, Gilmour J, Goyal R, Dally L, Sayeed E, Zachariah D, Ackland J, Kochhar S, Cox JH, Excler JL, Kumaraswami V, Paranjape R, Ramanathan VD. 2013. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised trial in HIV-uninfected Indian volunteers. PLoS One 8:e55831. http://dx.doi.org/10.1371/journal.pone.0055831.
21. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen YH, Dorrell L, McShane H, Schmidt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-Jones SL, Bwayo JJ, McMichael AJ, Hanke T. 2004. A human immunodeficiencyvirus1(HIV-1)cladeAvaccine in clinical trials: stimulation of HIV-specific T-cell responses byDNAand recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911-919. http://dx.doi.org/10.1099/vir.0.19701-0.
22. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J. 2007. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25:2120-2127. http://dx.doi.org/10.1016/j.vaccine.2006.11.016.
23. Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P. 2009. Aphase 1 study to evaluate the safety and immunogenicity of a recombinantHIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res. Hum. Retroviruses 25:1107-1116. http://dx.doi.org/10.1089/aid.2009.0096.
24. Sandström E, Nilsson C, Hejdeman B, Brave A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G. 2008. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198:1482-1490. http://dx.doi.org/10.1086/592507.
25. Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa Huang Y, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Dally L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD. 2010. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One 5:e8816. http://dx.doi.org/10.1371/journal.pone.0008816.
26. Bowie AG, Unterholzner L. 2008. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 8:911-922. http://dx.doi.org/10.1038/nri2436.
27. Bowie AG, Haga IR. 2005. The role of Toll-like receptors in the host response to viruses. Mol. Immunol. 42:859-867. http://dx.doi.org/10.1016/j.molimm.2004.11.007.
28. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11:373-384. http://dx.doi.org/10.1038/ni.1863.
29. Perdiguero B, Esteban M. 2009. The interferon system and vaccinia virus evasion mechanisms. J. Interferon Cytokine Res. 29:581-598. http://dx.doi.org/10.1089/jir.2009.0073.
30. González JM, Esteban M. 2010. A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol. J. 7:59. http://dx.doi.org/10.1186/1743-422X-7-59.
31. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 97:10162-10167. http://dx.doi.org/10.1073/pnas.160027697.
32. Lysakova-Devine T, Keogh B, Harrington B, Nagpal K, Halle A, Golenbock DT, Monie T, Bowie AG. 2010. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J. Immunol. 185:4261-4271. http://dx.doi.org/10.4049/jimmunol.1002013.
33. Oda S, Franklin E, Khan AR. 2011. Poxvirus A46 protein binds to TIR domaincontaining Mal/TIRAP via an alpha-helical sub-domain. Mol. Immunol. 48: 2144-2150. http://dx.doi.org/10.1016/j.molimm.2011.07.014.
34. Stack J, Bowie AG. 2012. Poxviral protein A46 antagonizes Toll-like receptor 4 signaling by targeting BB loop motifs in Toll-IL-1 receptor adaptor proteins to disrupt receptor:adaptor interactions. J. Biol. Chem. 287:22672-22682. http://dx.doi.org/10.1074/jbc.M112.349225.
35. Stack J, Haga IR, Schröder M, Bartlett NW, Maloney G, Reading PC, Fitzgerald KA, Smith GL, Bowie AG. 2005. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201:1007-1018. http://dx.doi.org/10.1084/jem.20041442.
36. Graham SC, Bahar MW, Cooray S, Chen RA, Whalen DM, Abrescia NG, Alderton D, Owens RJ, Stuart DI, Smith GL, Grimes JM. 2008. Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog. 4:e1000128. http://dx.doi.org/10.1371/journal.ppat.1000128.
37. Harte MT, Haga IR, Maloney G, Gray P, Reading PC, Bartlett NW, Smith GL, Bowie A, O'Neill LA. 2003. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 197:343-351. http://dx.doi.org/10.1084/jem.20021652.
38. Maloney G, Schröder M, Bowie AG. 2005. Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10. J. Biol. Chem. 280:30838-30844. http://dx.doi.org/10.1074/jbc.M501917200.
39. McCoy SL, Kurtz SE, Macarthur CJ, Trune DR, Hefeneider SH. 2005. Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation. J. Immunol. 174:3006-3014. http://www.jimmunol.org/content/174/5/3006.long.
40. Chen RA, Jacobs N, Smith GL. 2006. Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J. Gen. Virol. 87: 1451-1458. http://dx.doi.org/10.1099/vir.0.81736-0.
41. Chen RA, Ryzhakov G, Cooray S, Randow F, Smith GL. 2008. Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog. 4:e22. http://dx.doi.org/10.1371/journal.ppat.0040022.
42. García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M. 2011. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6:e24244. http://dx.doi.org/10.1371/journal.pone.0024244.
43. Sumner RP, Ren H, Smith GL. 2013. Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J. Gen. Virol. 94(Part 5):1121-1126. http://dx.doi.org/10.1099/vir.0.049700-0.
44. Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, Bourke NM, Randow F, Smith GL, Bowie AG. 2011. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog. 7:e1002247. http://dx.doi.org/10.1371/journal.ppat.1002247.
45. Benfield CT, Ren H, Lucas SJ, Bahsoun B, Smith GL. 2013. Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J. Gen. Virol. 94:1647-1657. http://dx.doi.org/10.1099/vir.0.052670-0.
46. Kalverda AP, Thompson GS, Vogel A, Schröder M, Bowie AG, Khan AR, Homans SW. 2009. Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J. Mol. Biol. 385:843-853. http://dx.doi.org/10.1016/j.jmb.2008.09.048.
47. Oda S, Schröder M, Khan AR. 2009. Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7. Structure 17:1528-1537. http://dx.doi.org/10.1016/j.str.2009.09.005.
48. Schröder M, Baran M, Bowie AG. 2008. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J. 27:2147-2157. http://dx.doi.org/10.1038/emboj.2008.143.
49. Aoyagi M, Zhai D, Jin C, Aleshin AE, Stec B, Reed JC, Liddington RC. 2007. Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci. 16:118-124. http://dx.doi.org/10.1110/ps.062454707.
50. Bartlett N, Symons JA, Tscharke DC, Smith GL. 2002. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J. Gen. Virol. 83:1965-1976. http://vir.sgmjournals.org/content/83/8/1965.long.
51. Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, Chen RA, Stuart DI, Grimes JM, Smith GL. 2007. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J. Gen. Virol. 88:1656-1666. http://dx.doi.org/10.1099/vir.0.82772-0.
52. DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, Arvikar S, Latz E, Fitzgerald KA, Marshall WL. 2004. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by Toll-like receptors. J. Biol. Chem. 279:36570-36578. http://dx.doi.org/10.1074/jbc.M400567200.
53. Jacobs N, Bartlett NW, Clark RH, Smith GL. 2008. Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection. J. Gen. Virol. 89:2877-2881. http://dx.doi.org/10.1099/vir.0.2008/004119-0.
54. Maluquer de Motes C, Cooray S, Ren H, Almeida GM, McGourty K, Bahar MW, Stuart DI, Grimes JM, Graham SC, Smith GL. 2011. Inhibition of apoptosis and NF-kappaB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog. 7:e1002430. http://dx.doi.org/10.1371/journal.ppat.1002430.
55. Morgan JR, Roberts BE. 1984. Organization of RNA transcripts from a vaccinia virus early gene cluster. J. Virol. 51:283-297.
56. Tamin A, Esposito J, Hruby D. 1991. A single nucleotide substitution in the 5'-untranslated region of the vaccinia N2L gene is responsible for both alpha-amanitin-resistant and temperature-sensitive phenotypes. Virology 182:393-396. http://dx.doi.org/10.1016/0042-6822(91)90688-8.
57. Tamin A, Villarreal EC, Weinrich SL, Hruby DE. 1988. Nucleotide sequence and molecular genetic analysis of the vaccinia virus HindIIIN/M region encoding the genes responsible for resistance to alpha-amanitin. Virology 165:141-150. http://dx.doi.org/10.1016/0042-6822(88)90667-8.
58. Zhang L, Villa NY, Rahman MM, Smallwood S, Shattuck D, Neff C, Dufford M, Lanchbury JS, Labaer J, McFadden G. 2009. Analysis of vaccinia virus-host protein-protein interactions: validations of yeast twohybrid screenings. J. Proteome Res. 8:4311-4318. http://dx.doi.org/10.1021/pr900491n.
59. Ferguson BJ, Benfield CT, Ren H, Lee VH, Frazer GL, Strnadova P, Sumner RP, Smith GL. 2013. Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J. Gen. Virol. 94:2070-2081. http://dx.doi.org/10.1099/vir.0.054114-0.
60. Gómez CE, Nájera JL, Jimenez EP, Jimenez V, Wagner R, Graf M, Frachette MJ, Liljestrom P, Pantaleo G, Esteban M. 2007. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strainsMVAand NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25:2863-2885. http://dx.doi.org/10.1016/j.vaccine.2006.09.090.
61. Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, Pique N, Gil C, Gatell JM, Esteban M, Gallart T. 2011. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One 6:e19644. http://dx.doi.org/10.1371/journal.pone.0019644.
62. García-Arriaza J, Arnaez P, Gómez CE, Sorzano CO, Esteban M. 2013. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS One 8:e66894. http://dx.doi.org/10.1371/journal.pone.0066894.
63. García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M. 2010. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5:e12395. http://dx.doi.org/10.1371/journal.pone.0012395.
64. Gómez CE, Nájera JL, Sanchez R, Jimenez V, Esteban M. 2009. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 27:3165-3174. http://dx.doi.org/10.1016/j.vaccine.2009.03.049.
65. Guerra S, González JM, Climent N, Reyburn H, Lopez-Fernandez LA, Nájera JL, Gómez CE, García F, Gatell JM, Gallart T, Esteban M. 2010. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J. Virol. 84:8141-8152. http://dx.doi.org/10.1128/JVI.00749-10.
66. + T-cell responses elicited by different poxvirusbased human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J. Virol. 82:2975-2988. http://dx.doi.org/10.1128/JVI.02216-07.
67. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, Petrilli V, Gómez CE, Perdiguero B, Tschopp J, Pantaleo G, Esteban M, Calandra T. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5:e1000480. http://dx.doi.org/10.1371/journal.ppat.1000480.
68. Ramírez JC, Gherardi MM, Esteban M. 2000. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B-and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74:923-933. http://dx.doi.org/10.1128/JVI.74.2.923-933.2000.
69. Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M. 2010. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5:e11406. http://dx.doi.org/10.1371/journal.pone.0011406.
70. Büttner M, Czerny CP, Lehner KH, Wertz K. 1995. Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet. Immunol. Immunopathol. 46:237-250. http://dx.doi.org/10.1016/0165-2427(94)05357-X.
71. Waibler Z, Anzaghe M, Ludwig H, Akira S, Weiss S, Sutter G, Kalinke U. 2007. Modified vaccinia virus Ankara induces Toll-like receptorindependent type I interferon responses. J. Virol. 81:12102-12110. http://dx.doi.org/10.1128/JVI.01190-07.
72. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Pantaleo G. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410:106-111. http://dx.doi.org/10.1038/35065118.
73. Sallusto F, Geginat J, Lanzavecchia A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-763. http://dx.doi.org/10.1146/annurev.immunol.22.012703.104702.
74. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712. http://dx.doi.org/10.1038/44385.
75. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258. http://dx.doi.org/10.1038/nri2274.
76. Bachmann MF, Wolint P, Schwarz K, Oxenius A. 2005. Recall proliferation potential of memory CD8+ T cells and antiviral protection. J. Immunol. 175: 4677-4685. http://www.jimmunol.org/content/175/7/4677.long.
77. McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554. http://dx.doi.org/10.1016/j.immuni.2010.09.011.
78. Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, Hill AV, Gilbert SC. 2008. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 3:e1638. http://dx.doi.org/10.1371/journal.pone.0001638.
79. Falivene J, Del Medico Zajac MP, Pascutti MF, Rodriguez AM, Maeto C, Perdiguero B, Gómez CE, Esteban M, Calamante G, Gherardi MM. 2012. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One 7:e32220. http://dx.doi.org/10.1371/journal.pone.0032220.
80. Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jimenez V, Roger T, Calandra T, Pantaleo G, Esteban M. 2012. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One 7:e48524. http://dx.doi.org/10.1371/journal.pone.0048524.
81. Garber DA, O'Mara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, Gill K, Verma M, Yu T, Johnson B, Li B, Derdeyn CA, Ibegbu C, Altman JD, Hunter E, Feinberg MB. 2012. Deletion of specific immunemodulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J. Virol. 86:12605-12615. http://dx.doi.org/10.1128/JVI.00246-12.
82. Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB. 2009. Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One 4:e5445. http://dx.doi.org/10.1371/journal.pone.0005445.
83. Perdiguero B, Gómez C, Di Pilato M, Sánchez Sorzano C, Delaloye J, Roger T, Calandra T, Pantaleo G, Esteban M. 2013. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity of the HIV/AIDS vaccine candidate NYVAC-C. PLoS One 8:e74831. http://dx.doi.org/10.1371/journal.pone.0074831.
84. Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jimenez V, González-Sanz R, Esteban M. 2012. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J. Virol. 86:5026-5038. http://dx.doi.org/10.1128/JVI.06684-11.
85. Kibler KV, Gómez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, González-Sanz R, Denzler K, Haddad EK, Wagner R, Sekaly RP, Tartaglia J, Pantaleo G, Jacobs BL, Esteban M. 2011. Improved NYVAC-based vaccine vectors. PLoS One 6:e25674. http://dx.doi.org/10.1371/journal.pone.0025674.
86. Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, Filali-Mouhim A, Goulet JP, Loof NM, Ossendorp F, Perdiguero B, Heinen P, Gómez CE, Kibler KV, Koelle DM, Sekaly RP, Sallusto F, Lanzavecchia A, Pantaleo G, Esteban M, Tartaglia J, Jacobs BL, Melief CJ. 2011. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 6:e16819. http://dx.doi.org/10.1371/journal.pone.0016819.
87. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Jr, Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527. http://dx.doi.org/10.1038/nature10003.
88. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M, Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15: 293-299. http://dx.doi.org/10.1038/nm.1935.
89. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425.
90. Antoine G, Scheiflinger F, Dorner F, Falkner FG. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396. http://dx.doi.org/10.1006/viro.1998.9123.
91. Blanchard TJ, Alcami A, Andrea P, Smith GL. 1998. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79(Part 5):1159-1167.
92. Meisinger-Henschel C, Schmidt M, Lukassen S, Linke B, Krause L, Konietzny S, Goesmann A, Howley P, Chaplin P, Suter M, Hausmann J. 2007. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol. 88:3249-3259. http://dx.doi.org/10.1099/vir.0.83156-0.
93. Nájera JL, Gómez CE, Domingo-Gil E, Gherardi MM, Esteban M. 2006. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J. Virol. 80:6033-6047. http://dx.doi.org/10.1128/JVI.02108-05.